TITLE

Discovery of Small-Molecule Inhibitors of HCV NS3-4A Protease as Potential Therapeutic Agents against HCV Infection

AUTHOR(S)
Shu-Hui Chen; Seng-Lai Tan
PUB. DATE
October 2005
SOURCE
Current Medicinal Chemistry;2005, Vol. 12 Issue 20, p2317
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic infection with hepatitis C virus (HCV) is associated with liver cirrhosis that often leads to hepatic failure and hepatocellular carcinoma (HCC). HCV infection has become a global health threat and the main cause of adult liver transplants in developed nations. Current approved anti-HCV therapies (interferon and pegylated interferon alone or in combination with ribavirin) are not effective in eliminating the viral infection in a significant population of patients (e.g., those infected with HCV genotype 1). Furthermore, these therapies are plagued with many undesirable side effects. Therefore, the HCV epidemic represents a huge unmet medical need that has triggered intensive research efforts towards the development of more effective drugs. Given its essential role in the process of HCV replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development. This is further fueled by the successful use of small-molecule inhibitors of the human immunodeficiency virus (HIV) viral protease, which have had an impressive effect on HIV-related morbidity and mortality, offering hope that analogous thugs might also have a similar impact against HCV. Here, we review the recent progress and development of small-molecule inhibitors of the HCV NS3/4A protease. In particular, we focus on the discovery of VX-950, the latest HCV NS3-4A protease inhibitor to be advanced to clinical studies. While the challenges of designing potent inhibitors of the viral protease have been solved, as highlighted by BILN 2061 and VX-950, it is still too early to determine whether these efforts will eventually yield promising drug candidates. For the emerging small-molecule HCV inhibitors, viral resistance will likely be a big problem. Thus, combination therapy of different drugs with different targets/mechanisms will be necessary to effectively inhibit HCV replication. It is also hoped that a detail characterization of how the resistance mutations that affect NS3 inhibitor binding may provide useful information for the design of inhibitors with the potential to treat resistant viruses that may arise during chronic HCV infection.
ACCESSION #
18105278

 

Related Articles

  • Treatment of hepatitis C. The 2002 French consensus. Dhumeaux, D.; marcellin, P.; Lerebours, E. // Gut;Dec2003, Vol. 52 Issue 12, p1784 

    Chronic infection by hepatitis C virus (HCV) affects 170 million people worldwide. In European countries the overall prevalence in adults ranges from 1% to 2%, and more than five million Europeans are thus infected. The high prevalence of HCV infection, together with the risk of severe...

  • Hepatitis C virus ARFP/F protein interacts with cellular MM-1 protein and enhances the gene trans-activation activity of c-Myc. Ma, Hsin-Chieh; Lin, Ta-Wei; Li, Huichun; Iguchi-Ariga, Sanae M. D.; Ariga, Hiroyoshi; Chuang, Yu-Li; Ou, Jing-Hsiung; Lo, Shih-Yen // Journal of Biomedical Science;Jul2008, Vol. 15 Issue 4, p417 

    The ARFP/F protein is synthesized from the +1 reading frame of the hepatitis C virus (HCV) core protein gene. The function of this protein remains unknown. To study the function of the HCV ARFP/F protein, we have conducted the yeast two-hybrid screening experiment to identify cellular proteins...

  • Iron Load and Serum Hepcidin in Hepatitis C Virus-Related Hepatocellular Carcinoma. Tawfik, Nehad M.; Hegazy, Mona A.; Abdel Maksoud, Inas A.; Nasr, Aml S. // Euroasian Journal of Hepato-Gastroenterology;Jan-Jun2012, Vol. 2 Issue 1, p24 

    Background: Hepatocellular carcinoma (HCC) is a major cause of death worldwide, and chronic inflammatory stress caused by hepatitis viruses plays a major role in HCC carcinogenesis. The aim of the present study was to investigate the expression of serum hepcidin and its correlation with iron...

  • A New Evolutionary Model for Hepatitis C Virus Chronic Infection. Gray, Rebecca R.; Salemi, Marco; Klenerman, Paul; Pybus, Oliver G. // PLoS Pathogens;May2012, Vol. 8 Issue 5, Special section p1 

    The authors discuss an evolutionary model for hepatitis C virus (HCV) chronic infection. They state that HCV infection affects about three percent of humanity and is a leading global cause of liver disease and liver cancer. They mention that an effective prevention and treatment of HCV infection...

  • HCV Virus and Lymphoid Neoplasms. Tsutsumi, Yutaka; Ito, Shinichi; Ogasawara, Reiki; Kudo, Kazuhiro; Tanaka, Junji; Asaka, Masahiro; Imamura, Masahiro // Advances in Hematology;2011, Vol. 2011, p1 

    Hepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (HCV-Ab) positive.We were able to perform pathological...

  • Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling. A. Lahm; A. Yagnik; A. Tramontano; U. Koch // Current Drug Targets;Aug2002, Vol. 3 Issue 4, p281 

    Hepatitis C virus (HCV), a member of the Flaviviridae family, has been recognised to be responsible for both parenterally transmitted and sporadic non-A and non-B hepatitis affecting 1-3% of the world population. HCV is a positive stranded RNA virus encoding a single polyprotein which contains...

  • Population-based Surveillance for Hepatitis C Virus, United States, 2006-2007. Klevens, R. Monina; Miller, Jeremy; Vonderwahl, Candace; Speers, Suzanne; Alelis, Karen; Sweet, Kristin; Rocchio, Elena; Poissant, Tasha; Vogt, Tara M.; Gallagher, Kathleen // Emerging Infectious Diseases;Sep2009, Vol. 15 Issue 9, p1499 

    Surveillance for hepatitis C virus infection in 6 US sites identified 20,285 newly reported cases in 12 months (report rate 69 cases/100,000 population, range 25-108/100,000). Staff reviewed 4 laboratory reports per new case. Local surveillance data can document the effects of disease, support...

  • A Proposed Method to Adjust for Selection Bias in Cohort Studies. Törner, Anna; Duberg, Ann-Sofi; Dickman, Paul; Svensson, Åke // American Journal of Epidemiology;Mar2010, Vol. 171 Issue 5, p602 

    Selection bias is a concern in cohort studies in which selection into the cohort is related to the studied outcome. An example is chronic infection with hepatitis C virus, where the initial infection may be asymptomatic for decades. This problem leads to selection of more severely ill...

  • Global control of hepatitis C: where challenge meets opportunity. Thomas, David L // Nature Medicine;Jul2013, Vol. 19 Issue 7, p850 

    We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics